Overview
Tirzepatide is a newer category of medication that acts on two appetite-regulating pathways (GIP and GLP-1) instead of one. It is one of several options a SHWCare clinician may discuss during the review process.
What Tirzepatide is
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It engages two pathways the body uses to regulate appetite and blood sugar. FDA-approved indications and branded products are reviewed by your clinician.
How it works
By engaging both the GIP and GLP-1 receptors, tirzepatide has been studied for its effects on appetite signaling and glucose handling. Member experiences vary; clinical outcomes are individual.
When a clinician may consider it
Members often discuss tirzepatide with their SHWCare clinician when they want to understand the differences between single-pathway (GLP-1 alone) and dual-pathway options. The clinician decides what is appropriate based on full intake.
Side effects discussed during review
Like other medications in this category, tirzepatide can cause nausea and digestive changes that typically lessen over time. A full personalized discussion of risks, benefits, and contraindications happens during the clinical review.
Cost & access
Costs and access vary by program. Your care coordinator will help compare options if multiple medications are appropriate.
